Literature DB >> 336005

Vascular access in a University transplant and dialysis program. Results, costs, and manpower implications.

S R Mandel, P L Martin, R L Blumoff, W D Mattern.   

Abstract

Vascular access has become the most common operation performed at North Carolina Memorial Hospital, Chapel Hill. Three hundred vascular access procedures performed between 1971 and 1975 were reviewed as to results, costs, and manpower commitment. Subcutaneous radial arterial venous fistula was the procedure of choice, with a 67% two-year patency and the lowest incidence of complications. An average of 1.7 operations per patient was necessary to maintain access. Patients used an average of 19 hospital days per year of dialysis for vascular access and an average of 35 hospital days per year of dialysis for all medical problems. Cost of hospitalization averaged $6,818 per patient per year of dialysis, and for vascular access alone averaged $3,452 per patient per year of dialysis. To create and maintain vascular access, 1,000 hours of operating room time were required, at an expense of $200,000. Vascular access in support of patients undergoing chronic hemodialysis requires a massive commitment of dollars, time, and personnel.

Entities:  

Mesh:

Year:  1977        PMID: 336005     DOI: 10.1001/archsurg.1977.01370110109012

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Percutaneous transluminal dilatation for restoration of angioaccess in chronic hemodialysis patients.

Authors:  P Probst; F Mahler; A Krneta; C Descoeudres
Journal:  Cardiovasc Intervent Radiol       Date:  1982       Impact factor: 2.740

2.  Early follow-up results of arteriovenous fistulae created for hemodialysis.

Authors:  Hikmet Iyem
Journal:  Vasc Health Risk Manag       Date:  2011-05-19

3.  Association between human resources and risk of hospitalisation in end-stage renal disease outpatients receiving haemodialysis: a longitudinal cohort study using claim data during 2013-2014.

Authors:  Hoon-Hee Choi; Kyu-Tae Han; Chung Mo Nam; Ki Tae Moon; Woorim Kim; Eun-Cheol Park
Journal:  BMJ Open       Date:  2016-08-17       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.